Case report: Ventricular fibrillation in patient who received ergotamine

Article Sidebar

JAN - JUN 2016 Vol 12 No 1 (2016)
PDF
Published: Mar 12, 2016
Keywords:
ergotism migraine ventricular fibrillation

Main Article Content

อุกฤษฎ์ อุเทนสุต
Department of Medicine, Wetchakarunrasm Hospital, Medical Service Department, Bangkok

Abstract

Patients who received ergotamine overdose or who had a drug that can cause drug-interaction with ergotamine may have ergotism. Ergotism is a serious complication that has many effects on blood vessels especially peripheral artery. This condition may presents in various types of symptom and sign including limb ischemia, cerebral ischemia and coronary ischemia etc. This case is 18 year old male with a history of taking ergotamine for 7 tabs in 24 hours. He presented to an emergency room with sudden unconsciousness and cardiac arrest, his EKG showed ventricular fibrillation. He died after 90 minutes of cardiopulmonary resuscitation.


 There are 2 cases report of ergotamine overdose which related to coronary ischemia cases, ventricular fibrillation and myocardial infarction but none of them are dead. This case is the first case report of a dead patient from ergotamine related ventricular fibrillation. However the autopsy was not done to confirm the definite diagnosis in this patient.


 


Keywords: ergotism, migraine, ventricular fibrillation

Article Details

How to Cite
อุเทนสุต อ. (2016). Case report: Ventricular fibrillation in patient who received ergotamine. Journal of Charoenkrung Pracharak Hospital, 12(1), 52–61. retrieved from https://he02.tci-thaijo.org/index.php/JCP/article/view/177733
Issue
Vol. 12 No. 1 (2016): JAN - JUN
Section
Case Report

References

1. Sanders-Bush E, Mayer S. 5-Hydroxytryptamine (Serotonin): receptor agonist and antagonist. In: Goodman Gilman A, Hardman JG, Limbird LE, editors. The Pharmacological basis of therapeutics. 10th ed. Buenos Aires: McGraw-Hill 2001; p.283-4.
2. Zavaleta EG, Fernandez BB, Grove MK, Kaye MD. St. Anthony’s fire (ergotamine induced leg ischemia)
a case report and review of the literature. Angiology 2001; 52: 349-56.
3. Eadie MJ. Clinically significant drug interactions with agents specific for migraine attacks. CNS Drugs. 2001; 15: 105-18.
4. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41-57.
5. Meyler WJ. Side effect of ergotamine. Cephalagia 1996; 16: 5-10.
6. Reynolds J. Martindale: The extra pharmacopoeia. London: Royal Pharmaceutical Society 1996; p.481-3.
7. Kumar GN, Rodrigues AD, Buko AM, Denisien JF. Cytochrome P-450 mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 227: 423-31.
8. Baldwin ZK, Ceraldi CC. Ergotism associated with HIV antiviral protease inhibitor therapy. J Vasc Surg
2003; 37: 676-8.
9. Velez Roa S, Preumont N, Mols P, Stoupel E, Renard M. Ventricular fibrillation secondary to ergotamine in a healthy young woman. Acta Cardiol 1999; 54: 283-6.
10. Liaudet L, Buclin T, Jaccard C, Eckert P. Drug points: Severe ergotism associated with interaction between ritonavir and ergotamine. BMJ 1999; 318 :771.
11. Yasue, Hirofumi, Takizawa, Akinori, Nagao, Masao. Acute myocardial infarction induced by ergotamine tartrate: possible role of coronary arterial spasm. Angiology 1981; 32: 414.
12. Roithinger FX, Punzengruber C, Gremmel F, Hinterreiter M, Holzner F, Pachinger O. Myocardial infarction after chronic ergotamine abuse. Eur Heart J 1993; 14: 1579-81.
13. BSAMA5 Bulletin der Schweizerischen Akademie der Medizinischen Wissenschaften. (Schwabe & Co., Steinentorstr. 13, CH-4010 Basel, Switzerland) V.1-1944: 2, 1, 1946/1947.
14. RPOBAR Research Progress in Organic-Biological and Medicinal Chemistry. (NewYork, NY) V.1-3, 1964-72. Discontinued. V.2; 284,1970.
15. Pardo Rey C, Yebra M, Borrallo M, Vega A, Ramos A, Montero MC. Irreversible coma, ergotamine, and ritonavir. Clin Infect Dis 2003; 37: 72-3.
16. Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F. Clinical ergotism induced by ritonavir. Scand J Infect Dis 2001; 33: 788-9.
17. Mortier E, Pouchot J, Vinceneux P, Lalande M. Ergotism related to interaction between nelfinavir and ergotamine. Am J Med 2001; 110: 594.
18. Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D. Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir. Postgrad Med J 1999; 75: 546-7.
19. Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP. Ergotism related to concurrent administration of ergotamine tartrate and indinavir. JAMA 1999; 281: 987.
20. Montero A, Giovannoni AG, Tvrde PL. Leg ischemia in a patient receiving ritonavir and ergotamine [letter]. Ann Intern Med 1999; 130: 329-30.